Marshall Wace LLP Makes New Investment in CareDx Inc (NASDAQ:CDNA)

Marshall Wace LLP acquired a new position in CareDx Inc (NASDAQ:CDNA) in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 6,967 shares of the company’s stock, valued at approximately $250,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Parametric Portfolio Associates LLC raised its holdings in CareDx by 0.9% in the second quarter. Parametric Portfolio Associates LLC now owns 50,257 shares of the company’s stock worth $1,809,000 after purchasing an additional 456 shares in the last quarter. State Board of Administration of Florida Retirement System increased its holdings in shares of CareDx by 6.9% during the first quarter. State Board of Administration of Florida Retirement System now owns 12,575 shares of the company’s stock valued at $396,000 after acquiring an additional 810 shares in the last quarter. Aperio Group LLC bought a new position in shares of CareDx during the second quarter valued at $31,000. Rhumbline Advisers increased its holdings in shares of CareDx by 2.2% during the first quarter. Rhumbline Advisers now owns 46,344 shares of the company’s stock valued at $1,461,000 after acquiring an additional 987 shares in the last quarter. Finally, Moody Aldrich Partners LLC increased its holdings in shares of CareDx by 2.8% during the second quarter. Moody Aldrich Partners LLC now owns 52,732 shares of the company’s stock valued at $1,898,000 after acquiring an additional 1,415 shares in the last quarter. Institutional investors and hedge funds own 92.49% of the company’s stock.

In related news, CEO Peter Maag sold 50,000 shares of CareDx stock in a transaction dated Tuesday, August 6th. The stock was sold at an average price of $28.84, for a total value of $1,442,000.00. Following the completion of the sale, the chief executive officer now directly owns 379,049 shares in the company, valued at approximately $10,931,773.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 3.20% of the stock is currently owned by company insiders.

Several equities analysts have recently weighed in on CDNA shares. Zacks Investment Research downgraded CareDx from a “hold” rating to a “sell” rating in a report on Tuesday. Craig Hallum started coverage on CareDx in a report on Tuesday. They set a “buy” rating and a $48.00 price target for the company. Raymond James raised their price target on CareDx from $46.00 to $48.00 and gave the company a “strong-buy” rating in a report on Friday, August 2nd. HC Wainwright set a $43.00 price target on CareDx and gave the company a “buy” rating in a report on Friday, August 23rd. Finally, BidaskClub upgraded CareDx from a “sell” rating to a “hold” rating in a report on Thursday. One research analyst has rated the stock with a sell rating, one has issued a hold rating, four have issued a buy rating and one has given a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $44.00.

NASDAQ CDNA opened at $26.17 on Friday. CareDx Inc has a one year low of $19.11 and a one year high of $41.27. The stock has a 50-day moving average of $22.90 and a 200 day moving average of $30.25. The company has a market capitalization of $1.10 billion, a price-to-earnings ratio of -19.98 and a beta of 0.92.

CareDx (NASDAQ:CDNA) last released its quarterly earnings data on Thursday, August 1st. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.07). CareDx had a negative return on equity of 47.53% and a negative net margin of 38.29%. The business had revenue of $31.45 million during the quarter, compared to the consensus estimate of $27.96 million. On average, equities research analysts anticipate that CareDx Inc will post -0.7 EPS for the current year.

CareDx Company Profile

CareDx, Inc operates as a transplant diagnostics company,which discovers, develops, and commercializes diagnostic solutions. Its product includes AlloMap, AlloSure, and Laboratory products. The company was founded on December 21, 1998 and is headquartered in Brisbane, CA.

See Also: How is a management fee different from a performance fee?

Institutional Ownership by Quarter for CareDx (NASDAQ:CDNA)

Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.